










Pharmaceuticals – Pipeline Overview¹ (as of February 27, 2025)

Phase I	Phase II	Phase III
HER2/mEGFR Inhibitor (BAY 2927088)  ●	HER2/mEGFR Inhibitor  ○ // Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)	Darolutamide (AR Inhibitor)  ○ // Adjuvant Prostate Cancer (DASL-HiCaP) // Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)
DGKzeta Inhibitor (BAY 2965501)  ●	Congestive Heart Failure rAAV Gene Therapy (AB-1002)  ● // Congestive Heart Failure (GenePHIT)	HER2/mEGFR Inhibitor  ● // Advanced Non-small Cell Lung Cancer with HER2 Activating Mutations, 1L (SOHO-02)
Lanerkitug (CCR8 Ab) (BAY 3375968)  ●	Anti-a2AP (BAY 3018250)  ● // Acute Ischemic Stroke; Pulmonary Embolism (SIRIUS)	Finerenone (MR Antagonist)  ○ // Non-diabetic Chronic Kidney Disease (FIND-CKD) // Chronic Kidney Disease in Type 1 Diabetes (FINE-ONE)
VVD KEAP1 Act (VVD-130037 aka NRF2 Inh, BAY 3605349)  ●	Nurandociguat (sGC Activator Oral) (BAY 3283142)  ● // Chronic Kidney Disease (ALPINE-1)	Vericiguat (sGC Stimulator)  ○ // Heart Failure (HFrEF) (VICTOR ²)
DGKalpha Inh (BAY 2862789)  ●	Parkinson's Disease rAAV Gene Therapy (AB-1005)  ● // Parkinson's Disease (REGENERATE-PD)	Asundexian (FX1a Inhibitor)  ● // 2 ^o Stroke Prevention (OCEANIC-STROKE)
225Ac-Pelgifatamab (BAY 3546828)  ●		Aflibercept 8mg (VEGF Inhibitor)  ○ // Retinal Vein Occlusion (QUASAR)
VVD STAT3 Inhibitor (VVD-130850, BAY 3630914)  ●		Gadoquatrane (High Relaxivity Contrast Agent)  ● // Magnetic Resonance Imaging (QUANTI-CNS, QUANTI-OBR)
225Ac-PSMA-Trillium (BAY 3563254)  ●		
SOS1 Inhibitor (BAY 3498264)  ●		
SEMA 3a (BAY 3401016)  ●		
Anti-coagulant (BAY 3389934)  ●		
Bemdaneprocel (Parkinson's Disease Cell Therapy) (BRT-DA01)  ●		
Multiple System Atrophy rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-MSA)  ●		
Pompe Disease rAAV Gene Therapy (ACTUS-101)  ●		
LGMD2I/R9 rAAV Gene Therapy (AB-1003 aka LION-101)  ●		
GPR84 Antagonist (BAY 3178275)  ●		
BAY 2701250  ●		

Submissions
Darolutamide (AR Inhibitor)  ○ // US, EU, CN: Prostate Cancer (mHSPC)
Finerenone (MR Antagonist)  ○ // US, EU, CN, JP: Heart Failure (HFmr/pEF)
Elinzanetant (Neurokinin-1,3 Rec Antagonist)  ● // US, EU: Vasomotor Symptoms
Aflibercept 8mg (VEGF-Inhibitor)  ○ // CN: Neovasc. Age-rel. Macular Degen. (nAMD)

-  Oncology
-  Cardiovascular+³
-  Neurology & Rare Diseases
-  Immunology
-  Others

-  New molecular entity
-  Life cycle management

 Protein Therapeutics
  Cell Therapy
  Contrast Agent
  Genetic Medicine
  Radionuclide Therapy
  Small Molecule

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit
² Conducted by Merck & Co ³ Including Precision Cardiovascular, Nephrology & Acute Care